Clinical Trial Update: The Therapeutic Efficacy of 18F-FDG Combined With 18F-FAPI PET/MR in Neoadjuvant Therapy for Gastric Cancer

View source ↗

Summary

An ongoing clinical trial is evaluating the use of combined 18F-FDG and 18F-FAPI PET/MR imaging in the neoadjuvant setting for gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• 18F-FAPI (Fluorine-18 labeled fibroblast activation protein inhibitor)
• 18F-FDG (fluorodeoxyglucose F-18)

Snippet

Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Conditions: Cancer | Status: RECRUITING